Evidence map›Paper›PMID 36964717›Full record

ArticleJournal of the National Cancer Institute2023

Evaluating colonoscopy screening intervals in patients with Lynch syndrome from a large Canadian registry.

Melyssa Aronson, Robert Gryfe, Yun-Hee Choi, Kara Semotiuk, Spring Holter, Thomas Ward, Steve Gallinger, Zane Cohen, Laurent Briollais

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Melyssa AronsonZane Cohen Centre, Sinai Health System and Faculty of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Robert GryfeDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Yun-Hee ChoiDepartment of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Kara SemotiukZane Cohen Centre, Sinai Health System and Faculty of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Spring HolterZane Cohen Centre, Sinai Health System, Toronto, ON, Canada.
Thomas WardZane Cohen Centre, Sinai Health System and Faculty of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Steve GallingerHepatobiliary/Pancreatic Surgical Oncology Program, University Health Network and Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Zane CohenZane Cohen Centre, Sinai Health System and Termerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Laurent BriollaisLunenfeld-Tanenbaum Research Institute, Sinai Health System and Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5741-9812
University of Toronto · CASinai Health System · CAUniversity Health Network · CAWestern University · CA

Funding

CIHR
6 · The paper itself

Abstract

backgroundLynch syndrome (LS) screening guidelines originally recommended colonoscopy every 1 to 2 years, beginning between the ages of 20 and 25 years. Recent studies have questioned the benefits of these short screening intervals in preventing colorectal cancer (CRC). Our goal is to determine how colonoscopy screening intervals impact CRC in patients with LS.

methodsWe analyzed the demographics, screening practices, and outcomes of patients with LS identified through the clinic based Familial Gastrointestinal Cancer Registry at the Zane Cohen Centre, Sinai Health System, Toronto, Canada.

resultsA total of 429 patients with LS were identified with median follow-up of 9.2 years; 44 developed CRC. We found a positive trend between shorter screening intervals and the number of adenomas detected during colonoscopy. Any new adenoma detected at screening decreased 10-year CRC incidence by 11.3%. For MLH1 carriers, a screening interval of 1-2 years vs 2-3 years led to a 20-year cumulative CRC risk reduction of 28% and 14% in females and males, respectively. For MSH2 carriers, this risk reduction was 29% and 17%, respectively, and for male MSH6 carriers 18%. Individuals without any adenomas detected (53.4% of LS carriers) had an increased 20-year CRC risk of 25.7% and 57.2% for women and men, respectively, compared with those diagnosed with adenomas at screening.

conclusionsThe recommended colonoscopy screening interval of 1-2 years is efficient at detecting adenomas and reducing CRC risk. The observation that 53.4% of LS patients never had an adenoma warrants further investigation about a possible adenoma-free pathway.

Indexed as

AdenomaColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisAdultCanadaColonoscopyFemaleHumansMaleRegistriesYoung Adult

Identifiers

PMID36964717
PMCPMC10323893
OpenAlexW4360942155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.